Serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with metastatic breast cancer

Oncology Reports

Volumn 7, Issue 6, 2000, Pages 1333-1338

  Maemura, Michio ^a   Iino, Yuichi ^a   Yokoe, Takao ^a   Takei, Hiroyuki ^a   Horiguchi, Jun ^a   Koibuchi, Yukio ^a   Ikeda, Fumihiro ^a   Ohwada, Susumu ^a   Takeyoshi, Izumi ^a   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Bone metastasis; Breast cancer; Pyridinoline cross linked carboxyterminal telopeptide of type I collagen

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; BONE TUMOR; BREAST TUMOR; FEMALE; HUMAN; METASTASIS; MIDDLE AGED; MONITORING; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM METASTASIS; PEPTIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 0034320494     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.6.1333     Document Type: Article

References (28)

1. Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66, 1987.
2. Perez DJ, Powles TJ, Milan J, Gazet JC, Ford HT, McCrcady VR, MacDonald JS and Coombcs RC: Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet 2: 613-616, 1983.
3. Galasko CS and Doyle FH: The detection of skeletal metastases from mammary cancer. A regional comparison between radiology and scintigraphy. Clin Radiol 23: 295-297, 1972.
4. Hortobagyi GN, Libshitz HI and Seabold JE: Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy. Cancer 53: 577-582, 1984.
5. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P and Distante V: Intensive diagnostic follow-up after treatment of primary breast cancer. JAMA 271: 1593-1597, 1994.
6. Burgeson RE: New collagens, new concepts. Annu Rev Cell Biol 4: 551-577, 1988.
7. Mundy OR: Mechanisms of bone metastasis. Cancer 80: 1546-1556, 1997.
8. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L and Risteli J: Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry. J Bone Miner Res 8: 127-132, 1993.
9. Charles P, Mosekilde L, Risteli L, Risteli J and Eriksen EF: Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 24: 81-94, 1994.
10. Berruti A, Dogliotti L, Gorzegno G, Torta M, Tampellini M, Tucci M, Cerutti S, Frezet MM, Stivanello M, Sacchetto G and Angeli A: Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 45: 1240-1247, 1999.
11. Risteli J, Elomaa I, Niemi S, Novamo A and Risteli L: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39: 635-640, 1993.
12. Akimoto S, Akakura K and Shimazaki J: Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Jpn J Clin Oncol 26: 157-163, 1996.
13. Takeuchi S and Saitoh H: Bone-turnover metabolites as clinical markers of bone metastasis in patients with prostatic carcinoma. Int J Urol 4: 368-373, 1997.
14. Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano M, Moriguchi H and Kitahara S: Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma. Cancer 80: 1760-1767, 1997.
15. Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S and Elomaa I: Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 73: 1074-1079, 1996.
16. Tahtela R and Tholix E: Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 16: 2289-2293, 1996.
17. Kobayashi T, Gabazza EC, Taguchi O, Risteli J, Risteli L, Kobayashi H, Yasui H, Yuda H, Sakai T, Kaneda M and Adachi Y: Type I collagen metabolites as tumor markers in patients with lung carcinoma. Cancer 85: 1951-1957, 1999.
18. Citrin DL, Hougen C, Zweibel W, Schlise S, Pruitt B, Ershler W, Davis TE, Harberg J and Cohen AI: The use of serial bone scans in assessing response of bone metastases to systemic treatment. Cancer 47: 680-685, 1981.
19. Bombardieri E, Martinetti A, Miceli R, Mariani L, Castellani MR and Seregni E: Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer? Eur J Nucl Med 24: 1349-1355, 1997.
20. Delmas PD: Biochemical markers of bone turnover. J Bone Miner Res 8: S549-S555, 1993.
21. Shimozuma K, Sonoo H, Fukunaga M, Ichihara K, Aoyama T and Tanaka K: Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol 29: 16-22, 1999.
22. Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G, Paccotti P, Dogliotti L and Angeli A: Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 73: 1581-1587, 1996.
23. Vinholes J, Coleman R, Lacombe D, Rose C, Tubiana-Hulin M, Bastit P, Wudiers J, Michel J, Leonard R. Nortier J, Mignolet F and Ford J: Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. Br J Cancer 80: 221-228, 1999.
24. Walls J. Assiri A. Howell A. Rogers E, Ratcliffe WA, Eastell R and Bundred NJ: Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases. Br J Cancer 80: 1265-1270, 1999.
25. Aruga A. Koizumi M. Hotta R. Takahashi S and Ogata E: Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76: 760-764, 1997.
26. Ricard-Blum S, Chossegros P, Guerret S, Trepo C, Grimaud JA and Chevallier M: The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) is a potential serum marker of ongoine liver fibrosis. Clin Chim Acta 248: 187-195, 1996.
27. Kushida K, Takahashi M, Kawana K and Inoue T: Comparison of markers for bone formation and resorption in premenopausal . and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80: 2447-2450, 1995.
28. Wenisch C, Bankl HC, Schonthal E, Myskiw D, Presterl E, Rumpold H and Graninger W: Serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter. Clin Immunol Immunopathol 75: 225-230, 1995.